Tuesday, 26 October 2021

 

 

LATEST NEWS Chiranjeevi lends his voice for Krishna Vamsi's 'Rangamarthanda' Emilia Clarke, Chiwetel Ejiofor land lead roles in sci-fi rom-com T20 World Cup: Mujeeb scalps five as Afghanistan thrash Scotland by 130 runs Prabhas' mythological drama readies for a wrap 'Bunty Aur Babli 2' debutante Sharvari had her PC moment on sets Amit Shah inaugurated and laid foundation stones of various development projects in Srinagar Amit Shah addressed the Sainik Sammelan at CRPF Camp, Lethpora, Pulwama Union MoS Women, Child Development & AYUSH visits Ayurvedic Hospital; Directorate of AYUSH Jammu Union MoS for Statistics, Programme Implementation conducts public outreach programme at KVS Chenani Tourism Directorate Jammu organises FAM Tour for Travel Trade Fraternity, Vloggers to Reasi Maiden Rowing, Kayaking competition in Ranjit Sagar Lake held on day 2 of Iconic Week festival at Basohli DDC Kishtwar reviews progress of key development projects FIEO, JKTPO organises Capacity Building Program on Commercialization of GI products at Jammu, Srinagar DDC Poonch reviews land acquisition cases of Army Tourism Directorate organises Mata Ka Jagran under Iconic Week Festival at Mahamaya & Kol Kandoli Temples All Party Meet Firmly Resolves To Oppose Centre’s Decision For Extension Of BSF’s Jurisdiction In Punjab AAP roars in all-party meeting, says Centre should not divide Punjab apart Amarinder Singh Raja Warring Hands Over Appointment Letters To Family Members Of Seven Farmers Lost Lives During Farmers' Agitation Daler Mehndi out with his new track 'Rola Pe Gaya' Supriya Pathak : No two mothers are same in real-life, same on-screen Naga Shaurya in place of Naga Chaitanya for 'Varudu Kaavalenu'

 

Covid recovery doesn't guarantee antibodies, immunity to re-infection

Delta Plus Covid variant, Delta Covid-19 variant, Coronavirus, Health, Research, Study, Researchers, COVID 19, Novel Coronavirus, Fight Against Corona, Covaxin, Covishield, Oxygen, Oxygen Cylinders, SARS-CoV-2, Sputnik V, Oxygen Plants, Pfizer, Astra Zeneca, Oxygen Concentrator, Remdesivir, Oxygen supply, Liquid Medical Oxygen, Oximeter

5 Dariya News

5 Dariya News

5 Dariya News

New York , 30 Aug 2021

Prior exposure to SARS-CoV-2, the virus causing Covid-19, neither guarantees a high level of antibodies nor immunity to re-infection as thought earlier, finds a study emphasising the need to get vaccinated against the deadly infectious disease.The study, led by researchers from the Northwestern University in the US, shows that two months after the second Pfizer/Moderna vaccination, antibody response decreases 20 per cent in adults with prior cases of Covid-19.It added that prior exposure to SARS-CoV-2 does not guarantee a robust antibody response to the first vaccine dose. This directly contradicts the assumption that contracting Covid will naturally make someone immune to re-infection.The findings, published in the journal Scientific Reports, further supports vaccination (and two doses), even for people who have contracted the virus previously."Many people, and many doctors, are assuming that any prior exposure to SARS-CoV-2 will confer immunity to re-infection. Based on this logic, some people with prior exposure don't think they need to get vaccinated. Or if they do get vaccinated, they think that they only need the first dose of the two-dose Pfizer/Moderna vaccines," said Thomas McDade, Professor of Anthropology in the Weinberg College of Arts and Sciences and a faculty fellow with the University's Institute for Policy Research.

"Our study shows that prior exposure to SARS-CoV-2 does not guarantee a high level of antibodies, nor does it guarantee a robust antibody response to the first vaccine dose. For people who had mild or asymptomatic infections, their antibody response to vaccination is essentially the same as it is for people who have not been previously exposed," he added.For the study, the team tested blood samples from adults who had contracted Covid to measure how long the immunity benefits of Pfizer and Moderna vaccines last and how well they protect from newer variants.When the team tested blood samples from participants collected about three weeks after their second vaccine dose, the average level of inhibition was 98 per cent, indicating a very high level of neutralising antibodies.The scientists tested emerging variants B.1.1351 (Beta), B.1.1.7 (Alpha) and P.1 (Gamma) and found the level of inhibition to viral variants was significantly lower, ranging from 67 per cent to 92 per cent.They also found that antibody response declined after two months by about 20 per cent, and that the antibody response to vaccination varied based on history of prior infection.Further, individuals with clinically confirmed cases of Covid-19 and multiple symptoms also showed a higher level of response than those who tested positive but had mild symptoms or were asymptomatic.

 

Tags: Delta Plus Covid variant , Delta Covid-19 variant , Coronavirus , Health , Research , Study , Researchers , COVID 19 , Novel Coronavirus , Fight Against Corona , Covaxin , Covishield , Oxygen , Oxygen Cylinders , SARS-CoV-2 , Sputnik V , Oxygen Plants , Pfizer , Astra Zeneca , Oxygen Concentrator , Remdesivir , Oxygen supply , Liquid Medical Oxygen , Oximeter

 

 

related news

 

 

 

Photo Gallery

 

 

Video Gallery

 

 

5 Dariya News RNI Code: PUNMUL/2011/49000
© 2011-2021 | 5 Dariya News | All Rights Reserved
Powered by: CDS PVT LTD